Ahead of print
Review paper
Published online: 2024-03-05

open access

Page views 155
Article views/downloads 30
Get Citation

Connect on Social Media

Connect on Social Media

Distal and proximal epithelioid sarcoma — differences in diagnosis and similarities in treatment

Maria Krotewicz1, Anna M. Czarnecka1, Piotr Błoński12, Jakub Śledź13, Bartłomiej Szostakowski1, Anna Szumera-Ciećkiewicz4, Ewa Bartnik56, Piotr Rutkowski1


Epithelioid sarcoma (ES) comprises two subtypes, distal and proximal. Initially, the distinction between these variants was based on tumor location, but subsequent research highlighted numerous functional differences between them. Proximal ES is distinguished by the molecular deletion of INI1, while classic ES is characterized by retained dysfunctional INI1 expression. Classic ES features elevated expression of GLI3, FYN, and CXCL12, along with overactive Notch/Hedgehog pathways and class 1 human leukocyte antigens (HLA). In contrast, proximal ES demonstrates MYC overexpression and upregulation of genes associated with the cell cycle, chromatin metabolism, and protein synthesis. The differences in clinical presentation underscore the necessity for tailored treatment approaches for each ES subtype. New therapeutic strategies are crucial, especially for the aggressive proximal variant. Tazemetostat, an oral selective inhibitor of the histone methyltransferase enhancer of zeste homolog 2 (EZH2), has recently gained FDA approval as a first-line treatment for ES patients.

Article available in PDF format

View PDF Download PDF file


  1. Laskowski J. Sarcoma aponeuroticum. Nowotwory. 1961; 11: 61–67.
  2. Enzinger FM. Epithelioid sarcoma.A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970; 26(5): 1029–1041, doi: 10.1002/1097-0142(197011)26:5<1029::aid-cncr2820260510>3.0.co;2-r.
  3. Czarnecka AM, Sobczuk P, Kostrzanowski M, et al. Epithelioid Sarcoma-From Genetics to Clinical Practice. Cancers (Basel). 2020; 12(8).
  4. Elsamna ST, Amer K, Elkattawy O, et al. Epithelioid sarcoma: half a century later. Acta Oncol. 2020; 59(1): 48–54.
  5. Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000; 7(3): 218–225.
  6. McCarville MB, Kao SC, Dao TV, et al. Magnetic resonance and computed tomography imaging features of epithelioid sarcoma in children and young adults with pathological and clinical correlation: a report from Children's Oncology Group study ARST0332. Pediatr Radiol. 2019; 49(7): 922–932.
  7. Armah H, Parwani A. Epithelioid Sarcoma. Arch Pathol Lab Med. 2009; 133(5): 814–819.
  8. Frezza AM, Botta L, Pasquali S, et al. An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES). Ann Oncol. 2017; 28: v525.
  9. Chase D, Enzinger F. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985; 9(4): 241–263.
  10. Farzaliyev F, Steinau HU, Ring A, et al. Classic Type of Epithelioid Sarcoma of the Distal Upper Extremity: Clinical and Oncological Characteristics. Hand (N Y). 2023; 18(6): 1037–1043.
  11. Guillou L, Wadden C, Coindre JM, et al. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997; 21(2): 130–146.
  12. Sakharpe A, Lahat G, Gulamhusein T, et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist. 2011; 16(4): 512–522.
  13. Raoux D, Péoc'h M, Pedeutour F, et al. Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol. 2009; 33(6): 954–958.
  14. Lu H, Xu Q, Chen X, et al. Clinical characteristics and survival analysis of patients with limb epithelioid sarcoma. Medicine (Baltimore). 2022; 101(30): e29969.
  15. Kaya EA, Broadbent TJ, Thomas CJ, et al. Primary Epithelioid Sarcoma of Orbit: A Case Report and Review of the Literature. Case Rep Oncol Med. 2018; 2018: 3989716.
  16. Zhang Y, Mirpuri TM, Ho CL. Primary Epithelioid Sarcoma Manifesting as a Fungating Scalp Mass - Imaging Features and Treatment Options. A Case Report and Literature Review. J Radiol Case Rep. 2021; 15(11): 1–9.
  17. Del Savio E, Maestro R. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma. Cells. 2022; 11(17).
  18. Li Y, Cao G, Tao X, et al. Clinicopathologic features of epithelioid sarcoma: report of seventeen cases and review of literature. Int J Clin Exp Pathol. 2019; 12(8): 3042–3048.
  19. Gajdzis P, Laé M, Klijanienko J. FNA of epithelioid sarcoma: Curie Institute experience and critical review of the literature. Cancer Cytopathol. 2018; 126(11): 934–941.
  20. Mannan AA, Rifaat AA, Kahvic M, et al. Proximal-type epithelioid sarcoma in the groin presenting as a diagnostic dilemma. Pathol Oncol Res. 2010; 16(2): 181–188.
  21. Noujaim J, Thway K, Bajwa Z, et al. Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Front Oncol. 2015; 5: 186.
  22. Pendse AA, Dodd LG. Fine-needle-aspiration cytology of a proximal type epithelioid sarcoma: A case report. Diagn Cytopathol. 2015; 43(10): 859–862.
  23. Fletcher CDM, Unni K, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon 2002.
  24. Casanova M, Ferrari A, Collini P, et al. Italian Soft Tissue Sarcoma Committee. Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer. 2006; 106(3): 708–717.
  25. Alves A, Constantinidou A, Thway K, et al. The evolving management of epithelioid sarcoma. Eur J Cancer Care (Engl). 2021; 30(6): e13489.
  26. Folpe AL. Selected topics in the pathology of epithelioid soft tissue tumors. Mod Pathol. 2014; 27 Suppl 1: S64–S79.
  27. Needs T, Fillman EP. Epithelioid Sarcoma. In: Fillman EP. ed. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2023.
  28. Baratti D, Pennacchioli E, Casali PG, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007; 14(12): 3542–3551.
  29. de Visscher SA, van Ginkel RJ, Wobbes T, et al. Epithelioid sarcoma: Still an only surgically curable disease. Cancer. 2006; 107(3): 606–612.
  30. Zhang S, Jing C, Liu H, et al. Epithelioid sarcoma: A single-institutional retrospective cohort study of 36 cases. J Orthop Surg (Hong Kong). 2021; 29(3): 23094990211029349.
  31. Jawad MU, Extein J, Min ES, et al. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res. 2009; 467(11): 2939–2948.
  32. Frezza AM, Sbaraglia M, Lo Vullo S, et al. The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. Eur J Surg Oncol. 2020; 46(7): 1320–1326.
  33. Rekhi B, Thomas A. A case of retroperitoneal tumor displaying epithelial differentiation, prominent myxoid stroma and loss of INI1/SMARCB1. Pathologica. 2021; 113(6): 456–462.
  34. Kato H, Hatori M, Watanabe M, et al. Epithelioid sarcomas with elevated serum CA125: report of two cases. Jpn J Clin Oncol. 2003; 33(3): 141–144.
  35. Mukai M, Torikata C, Iri H, et al. Cellular differentiation of epithelioid sarcoma. An electron-microscopic, enzyme-histochemical, and immunohistochemical study. Am J Pathol. 1985; 119(1): 44–56.
  36. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009; 131(2): 222–227.
  37. Magetsari R, Dwianingsih EK, Putro YA, et al. Primary rhabdoid epithelioid sarcoma of the left thigh mimicking epithelioid rhabdomyosarcoma: A diagnostic pitfall. Int J Surg Case Rep. 2020; 70: 188–192.
  38. Diaz-Perez JA, Spasic S, Velez-Torres JM, et al. Epithelioid Sarcoma of the Peripheral Nerve: Clinicopathologic Series of Three Cases and Literature Review. Am J Clin Pathol. 2021; 155(5): 729–737.
  39. Miettinen M, Wang Z, Sarlomo-Rikala M, et al. ERG Expression in Epithelioid Sarcoma. Am J Surg Pathol. 2013; 37(10): 1580–1585.
  40. Rasmussen SV, Jin JX, Bickford LR, et al. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. Clin Transl Med. 2022; 12(7): e961.
  41. Ramaglia M, D'Angelo V, Iannotta A, et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016; 16: 59.
  42. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008; 129(6): 705–733.
  43. Lee HI, Kang KH, Cho YM, et al. Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. Arch Pathol Lab Med. 2006; 130(6): 871–874.
  44. Lokshin A, Bast RC, Rodland K. Circulating Cancer Biomarkers. Cancers (Basel). 2021; 13(4).
  45. Mularz K, Harazin-Lechowska A, Ambicka A, et al. Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma. Pol J Pathol. 2012; 63(3): 179–183.
  46. Cooper GW, Hong AL. SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities. Cancers (Basel). 2022; 14(15).
  47. Frezza A, Sigalotti L, Savio ED, et al. Epitheliod sarcoma: Molecular insights into proximal versus classic variant. J Clin Oncol. 2020; 38(15_suppl): e23552–e23552.
  48. Wang X, Haswell JR, Roberts CWM. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res. 2014; 20(1): 21–27.
  49. Sullivan LM, Folpe AL, Pawel BR, et al. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol. 2013; 26(3): 385–392.
  50. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005; 65(10): 4012–4019.
  51. Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017; 108(4): 547–552.
  52. Nacev BA, Jones KB, Intlekofer AM, et al. The epigenomics of sarcoma. Nat Rev Cancer. 2020; 20(10): 608–623.
  53. Imura Y, Yasui H, Outani H, et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer. 2014; 13: 185.
  54. Darr J, Klochendler A, Isaac S, et al. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis. Oncogene. 2014; 33(23): 3024–3032.
  55. Chico MA, Mesas C, Doello K, et al. Cancer Stem Cells in Sarcomas: In Vitro Isolation and Role as Prognostic Markers: A Systematic Review. Cancers (Basel). 2023; 15(9).
  56. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020; 13(1): 104.
  57. Schaefer IM, Al-Ibraheemi A, Qian X. Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms. Am J Clin Pathol. 2021; 156(2): 229–245.
  58. Izumi T, Oda Y, Hasegawa T, et al. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod Pathol. 2006; 19(6): 820–831.
  59. Frezza AM, Jones RL, Lo Vullo S, et al. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018; 4(9): e180219.
  60. Thway K, Jones RL, Noujaim J, et al. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016; 23(1): 41–49.
  61. Alexander L. Epithelioid Sarcoma of Upper Extremity: Diagnostic Dilemma With Therapeutic Challenges. Cureus. 2021; 13(3): e14156.
  62. Sajko N, Murphy S, Tran A. Undifferentiated epithelioid sarcoma presenting as a fever of unknown origin: a case report. J Med Case Rep. 2019; 13(1): 24.
  63. Asano N, Yoshida A, Ogura K, et al. Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma: A Multi-Institutional Retrospective Study of 44 Patients. Ann Surg Oncol. 2015; 22(8): 2624–2632.
  64. Zegarra Buitron E, Vidal Panduro DA, Morales Luna D. Clinicopathological Characteristics, Treatment, and Survival in Patients Diagnosed With Proximal-Type Epithelioid Sarcoma: A Case Report and Systematic Review. Cureus. 2022; 14(12): e32962.
  65. Carbone A, Gloghini A, Volpe R. The value of immunohistochemistry in the diagnosis of soft tissue sarcomas. Ann Oncol. 1992; 3 Suppl 2: S51–S54.
  66. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021; 113(2): 70–84.
  67. Mahajan A, Sen I, Hazra D, et al. Management of Epithelioid Sarcoma of the Inguinal Region with Vascular Invasion. Indian J Surg. 2016; 78(4): 315–317.
  68. Yuan J, Li X, Yu S. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. Cancer Control. 2021; 28: 10732748211038424.
  69. Dangoor A, Seddon B, Gerrand C, et al. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016; 6: 20.
  70. Spałek MJ, Koseła-Paterczyk H, Borkowska A, et al. Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2021; 110(4): 1053–1063.
  71. Sobanko JF, Meijer L, Nigra TP. Epithelioid sarcoma: a review and update. J Clin Aesthet Dermatol. 2009; 2(5): 49–54.
  72. Chmiel P, Krotewicz M, Szumera-Ciećkiewicz A, et al. Review on Lymph Node Metastases, Sentinel Lymph Node Biopsy, and Lymphadenectomy in Sarcoma. Curr Oncol. 2024; 31(1): 307–323.
  73. Liu QK, Yu XJ, Wang YG, et al. Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection. J Orthop Surg Res. 2022; 17(1): 167.
  74. Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol. 2022; 13(2): 158–163.
  75. Russi S, Sgambato A, Bochicchio AM, et al. CHIR99021, trough GSK-3β Targeting, Reduces Epithelioid Sarcoma Cell Proliferation by Activating Mitotic Catastrophe and Autophagy. Int J Mol Sci. 2021; 22(20).
  76. Meissner M, Napolitano A, Thway K, et al. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure? Expert Opin Pharmacother. 2023; 24(12): 1395–1401.